Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.73 |
| ▸ | PGR | P06401 | 5/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | TSHR | P16473 | 5/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.73 |
| ▸ | AR | P10275 | 4/20 | 0.73 |
| ▸ | BLM | P54132 | 3/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930380 | 1.00 | SMN1; SMN2 (0.73) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| SCHEMBL9943274 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| SCHEMBL9943275 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| SCHEMBL13327486 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12858540 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL14193742 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL13304392 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177786 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12153588 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL258031 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2011-01-06 | — | — | US | claimed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | claimed |
| EP-2077844-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | Jennings-Spring, Barbara L. (US) | 2009-07-15 | — | — | EP | claimed |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | JENNINGS-SPRING BARBARA L | 2008-06-12 | — | — | US | claimed |
| WO-2008066634-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | JENNINGS-SPRING BARBARA L (US) | 2008-06-05 | — | — | WO | claimed |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2008-05-01 | — | — | US | claimed |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2022-04-14 | — | — | US | disclosed |
| US-20160143927-A1 | Compounds, Methods, and Treatments for Abnormal Signaling Pathways for Prenatal and Postnatal Development | JENNINGS BARBARA BROOKE (US) | 2016-05-26 | — | — | US | disclosed |
| US-20110218176-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS-SPRING BARBARA BROOKE | 2011-09-08 | — | — | US | disclosed |
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2011-01-06 | — | — | US | disclosed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | disclosed |
| EP-2077844-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | Jennings-Spring, Barbara L. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | JENNINGS-SPRING BARBARA L | 2008-06-12 | — | — | US | disclosed |
| WO-2008066634-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | JENNINGS-SPRING BARBARA L (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, PKM, PDK2 | SMN1; SMN2 1817/4885HSD17B10 2523/4885ALDH1A1 1478/4885 |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | SMN1; SMN2 942/4885HSD17B10 2850/4885ALDH1A1 2608/4885 |
| US-20160143927-A1 | Compounds, Methods, and Treatments for Abnormal Signaling Pathways for Prenatal and Postnatal Development | PDK1, PKM, PDK2 | SMN1; SMN2 1799/4885HSD17B10 2584/4885ALDH1A1 1758/4885 |
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | SMN1; SMN2 1684/4885HSD17B10 821/4885ALDH1A1 2087/4885 |
| US-20110218176-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | PDK1, PKM, PDK2 | SMN1; SMN2 1799/4885HSD17B10 2584/4885ALDH1A1 1758/4885 |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | PGF, ERH, BRCA1 | SMN1; SMN2 1127/4885HSD17B10 2395/4885ALDH1A1 2034/4885 |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | PDK1, PKM, PDK2 | SMN1; SMN2 1817/4885HSD17B10 2523/4885ALDH1A1 1478/4885 |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | SMN1; SMN2 1684/4885HSD17B10 821/4885ALDH1A1 2087/4885 |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | SHH, ERH, CDK5 | SMN1; SMN2 1174/4885HSD17B10 2418/4885ALDH1A1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.